Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market

Home / News / Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market


https://eyewire.news/articles/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/



            
                
                                            Recent NewsCovid-19 vaccine update: Bharat Biotech’s Covaxin to undergo trial in Bangladesh? All you need to know
Bhopal Hospital’s Serious Breach of Covaxin Trial Protocols Could Prove Costly
Indian state asks govt to stop sending Covaxin vaccine doses as it won’t use them until efficacy data published
Vaccination reaches 2nd leg but Covaxin yet to gain acceptance
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market
			
	
		
	



	
		About Us
	
	
		
	



	
		In 1993, Biogenetech started with just 10 staff, distributing diagnostic kits and nuclear medicines.

In the past 25 years, Biogenetech introduced more than 15 innovative vaccines and pharmaceuticals, contributing to the improvements in public health standards in Thailand, protecting our population from numerous infectious diseases!

	



	
	Read More


        

        
                    
                
                    Related Health Education
                                        
                        
                            
                                
                                    Bhopal Hospital’s Serious Breach of Covaxin Trial Protocols Could Prove Costly                                
                            
                        
                                        
                        
                            
                                
                                    Indian state asks govt to stop sending Covaxin vaccine doses as it won’t use them until efficacy data published                                
                            
                        
                                        
                        
                            
                                
                                    Vaccination reaches 2nd leg but Covaxin yet to gain acceptance                                
                            
                        
                                        
                        
                            
                                
                                    India’s Covaxin vaccine likely effective against UK SARS-CoV-2 variant: Study                                
                            
                        
                                        
                        
                            
                                
                                    Coronavirus News: new Study Finds That SARS-CoV-2 Coronavirus is Able to Withstand Extreme Temperature Fluctuations

Related Posts

Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Market

Related Health Education